Publications by authors named "Ronald Peck"

Claim this Profile
S
Symbiotic T6SS affects horizontal transmission of among amoeba hosts.
Anna Chen, Rachel M Covitz, Abigail A Folsom, Xiangxi Mu, Ronald F Peck

ISME Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fermentation Gone Wild: A Biochemistry Laboratory Experiment.
Julie T Millard, Ronald F Peck, Tina M Beachy, Victoria L Hepburn

J Chem Educ· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species Widely Distributed in Halophilic Archaea Exhibit Opsin-Mediated Inhibition of Bacterioruberin Biosynthesis.
Ronald F Peck, Serena M Graham, Abby M Gregory

J Bacteriol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Patient and Clinician Communication-Priming Intervention on Patient-Reported Goals-of-Care Discussions Between Patients With Serious Illness and Clinicians: A Randomized Clinical Trial.
J Randall Curtis, Lois Downey, Anthony L Back, Elizabeth L Nielsen, Sudiptho Paul, Ronald Peck

JAMA Intern Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opsin-Mediated Inhibition of Bacterioruberin Synthesis in Halophilic Archaea.
Ronald F Peck, Alexandru M Pleşa, Serena M Graham, David R Angelini, Emily L Shaw

J Bacteriol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Maximilian Stahl, Richard Gedrich, Ronald Peck, Theresa LaVallee, Joseph Paul Eder

Immunotherapy· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.
David Berman, Alan Korman, Ronald Peck, David Feltquate, Nils Lonberg

Pharmacol Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular trafficking and glycobiology of TbPDI2, a stage-specific protein disulfide isomerase in Trypanosoma brucei.
Kevin J Schwartz, Ronald F Peck, James D Bangs

Eukaryot Cell· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Linda T Vahdat, Eva S Thomas, Henri H Roché, Gabriel N Hortobagyi, Joseph A Sparano, Ronald A Peck

Support Care Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jacek Jassem, Luis Fein, Mark Karwal, Mario Campone, Ronald Peck

Breast· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Patricia K Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, Lucinda Orsini, Shima Safikhani

Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bacterioopsin-mediated regulation of bacterioruberin biosynthesis in Halobacterium salinarum.
Antoinette M Dummer, Jessica C Bonsall, Jacob B Cihla, Stephanie M Lawry, Gabriela C Johnson, Ronald F Peck

J Bacteriol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
Henri Roché, Pierfranco Conte, Edith A Perez, Joseph A Sparano, Binghe Xu, Ronald Peck

Breast Cancer Res Treat· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Gabriel N Hortobagyi, Henry L Gomez, Rubi K Li, Hyun-Cheol Chung, Luis E Fein, Ronald A Peck

Breast Cancer Res Treat· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Joseph A Sparano, Eduard Vrdoljak, Oliver Rixe, Binghe Xu, Alexey Manikhas, Ronald Peck

J Clin Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of hand-held models and computer imaging programs helps students answer oral questions about molecular structure and function: a controlled investigation of student learning.
Michelle A Harris, Ronald F Peck, Shannon Colton, Jennifer Morris, Elias Chaibub Neto

CBE Life Sci Educ· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Ahmad Awada, Martine J Piccart, Suzanne F Jones, Ronald A Peck, Thierry Gil

Cancer Chemother Pharmacol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Craig Bunnell, Linda Vahdat, Lee Schwartzberg, Julie Gralow, Judith Klimovsky, Ronald Peck

Clin Breast Cancer· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LAMP-like protein p67 plays an essential role in the lysosome of African trypanosomes.
Ronald F Peck, April M Shiflett, Kevin J Schwartz, Amanda McCann, Stephen L Hajduk

Mol Microbiol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Sandrine Faivre, Catherine Delbaldo, Valérie Boige, Patricia Pautier, Jean-Charles Soria, Ronald Peck

Eur J Cancer· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Eva S Thomas, Henry L Gomez, Rubi K Li, Hyun-Cheol Chung, Luis E Fein, Ronald A Peck

J Clin Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Henri Roché, Louise Yelle, Francesco Cognetti, Louis Mauriac, Craig Bunnell, Ronald Peck

J Clin Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Johan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, Jean-Luc Breton, Philip Bonomi, Ronald Peck

J Clin Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Edith A Perez, Guillermo Lerzo, Xavier Pivot, Eva Thomas, Linda Vahdat, Ronald Peck

J Clin Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis